We audited the marketing at Character Biosciences
Precision medicine for AMD using genomics and AI
This page was built using the same AI infrastructure we deploy for clients.
Month-to-month. Cancel anytime.
Limited visibility in precision medicine and AMD drug discovery search results despite deep technical differentiation in genetic subtyping
Early-stage founder LinkedIn presence underutilized relative to $137M raised and clinical trial momentum
Minimal paid presence targeting pharma partnerships, patient recruitment, and clinical trial investigator outreach
AI-Forward Companies Trust MarketerHire
Plaid
MasterClass
Constant Contact
Netflix
Noom
TinuitiCharacter Biosciences's Leadership
We mapped your current team to understand where MH-1 fits in.
MH-1 doesn't replace your team. It becomes your marketing team: dedicated humans + AI agents running execution at scale while you focus on product.
Here's Where You Stand
Series B biotech with strong IP and partnerships but emerging marketing infrastructure. Growth phase requires scaled visibility.
Ranking for branded terms and some precision medicine queries, but underutilized for AMD reclassification, CTX114, CTX203 discovery
MH-1: SEO agent builds clinical trial recruitment content and gene subtype education targeting ophthalmologists and patient communities
Minimal structured data and fact panels around genomic subtypes, CTX programs, and AMD phenotyping breakthroughs
MH-1: AEO agent surfaces deep phenotyping methodology and lead program details in LLM responses to precision medicine and clinical trial queries
No visible campaigns targeting investigator recruitment, partnership sourcing, or patient pre-trial education channels
MH-1: Paid agent runs targeted campaigns to ophthalmology opinion leaders, clinical trial networks, and patient advocacy groups
Cofounder credentials strong but limited published content on genomic stratification, trial learnings, or competitive positioning
MH-1: Content agent publishes whitepapers, webinar series on AMD genetics, and competitive analyses positioning precision medicine advantage
No visible nurture for ophthalmology clinic partners, patient registries, or institutional investor communications post-funding
MH-1: Lifecycle agent nurtures clinic partnerships with trial readiness playbooks and tracks investor sentiment on precision oncology comparables
Top Growth Opportunities
150 clinic partnerships represent distribution but lack centralized recruitment motion. Investigators need patient identification tools and trial readiness resources.
Content and paid agents co-create investigator toolkits, patient pre-screening webinars, and targeted outreach to high-volume ophthalmology centers
CTX114 and CTX203 advancement require pharma deal flow. Current messaging lacks proof of precision medicine ROI versus monotherapy competitors.
LinkedIn agent positions Cheng and Nick as precision medicine architects. Paid agent targets pharma business development with data-driven case studies
AMD patient communities and advocacy groups drive clinical trial enrollment and real-world evidence. Limited community presence or patient education content.
Content agent builds patient-friendly education on AMD genetic subtypes and how precision medicine changes outcomes. Outbound targets key advocates
3 Humans + 7 AI Agents
A dedicated marketing team built specifically for Character Biosciences. The humans handle strategy and judgment. The AI agents handle execution at scale.
Human Experts
Owns Character Biosciences's growth roadmap. Pipeline strategy, account expansion playbooks, board-ready reporting. Translates AI insights into revenue.
Runs paid acquisition across LinkedIn and Google. Manages creative testing, budget allocation, and pipeline attribution.
Builds thought leadership on LinkedIn. Creates long-form content targeting your ICP. Manages the content-to-pipeline engine.
AI Agents
Monitors AI citation visibility across 6 LLMs weekly. Builds content targeting category queries to increase Character Biosciences's presence in AI-generated answers.
Produces LinkedIn ad variants targeting your ICP. Tests headlines, visuals, and offers at 10x the speed of manual production.
Builds lifecycle sequences: onboarding, expansion triggers, champion nurture, and re-engagement for dormant accounts.
Founder thought leadership. Builds the narrative that drives enterprise inbound from senior decision-makers.
Tracks competitors. Monitors positioning changes, ad spend, content strategy. Informs your counter-positioning.
Attribution by channel, pipeline velocity, budget waste detection. Weekly synthesis reports with AI-generated recommendations.
Weekly market intelligence digest curated from Character Biosciences's industry signals. Positions you as the intelligence layer. Drives inbound pipeline from subscribers.
Active Workflows
Here's what the MH-1 system would be doing for Character Biosciences from week 1.
AEO workflow surfaces Character Bio's genomic subtyping and CTX program details when researchers query AMD precision medicine, genetic ophthalmology, and clinical trial advances
LinkedIn workflow positions Cheng Zhang and Nick Johnson as precision medicine architects through thought leadership on AMD genetics, data integration, and drug discovery AI
Paid workflow targets ophthalmology opinion leaders, clinical trial networks, and pharma business development teams with investigator recruitment and partnership case studies
Lifecycle workflow nurtures clinic partners with trial readiness playbooks, investigator webinars, and patient recruitment resources. Tracks investor thesis alignment
Competitive watch monitors announcements from SmartPharm, Celsius, Defense Therapeutics and tracks AMD precision medicine discourse to identify positioning gaps
Pipeline intelligence identifies high-volume ophthalmology centers, pharma licensing prospects, and patient advocacy influencers aligned with CTX trial readiness
Traditional Marketing vs. MH-1
Traditional Approach
MH-1 System
Audit. Sprint. Optimize.
3 phases. Real output every 2 weeks. You see results, not decks.
AI Audit + Growth Roadmap
Full diagnostic of Character Biosciences's marketing infrastructure: SEO, AEO visibility, paid, content, lifecycle. Prioritized roadmap tied to pipeline metrics. Delivered in 7 days.
Sprint-Based Execution
2-week sprint cycles. Real campaigns, not presentations. Each sprint ships measurable output across your priority channels.
Compounding Intelligence
AI agents monitor your channels 24/7. They catch budget waste, detect creative fatigue, track AI citation changes, and run A/B experiments autonomously. Week 12 is measurably better than week 1.
AI Marketing Operating System
3 elite humans + AI agents operating your growth system
Output multiplier: ~10x output at a fraction of the cost. The system gets smarter every week.
Month-to-month. Cancel anytime.
Common Questions
How does MH-1 differ from a marketing agency?
MH-1 pairs 3 elite human marketers with 7 AI agents. The humans handle strategy, creative direction, and judgment calls. The AI agents handle execution at scale: generating ad variants, monitoring competitors, building email sequences, tracking citations across LLMs, running A/B experiments autonomously. You get the quality of a senior marketing team with the output volume of a 15-person department.
What kind of results can we expect in the first 90 days?
First 90 days focus on clinical trial recruitment and pharma partnership visibility. SEO agent optimizes for investigator and partner discovery. Content agent publishes trial readiness playbooks and AMD genetics whitepapers. Paid agent launches targeted campaigns to ophthalmology networks and pharma business development. AEO agent seeds your precision medicine methodology into LLM responses. LinkedIn agent builds founder authority. By day 90, expect increased investigator inquiries, clinic engagement, and pharma inbound.
How does Character Bio appear in AI responses about AMD precision medicine
Currently, Character Bio's deep phenotyping and genetic reclassification approach rarely surfaces in LLM answers about AMD subtypes or precision ophthalmology. MH-1 AEO agent embeds structured data about your genomic stratification methodology and CTX programs so when researchers and clinicians ask about precision medicine for AMD, your differentiation appears prominently in AI-generated responses.
Can we cancel anytime?
Yes. MH-1 is month-to-month with no long-term contracts. We earn your business every sprint. That said, compounding effects kick in around month 3 as the AI agents accumulate data and the system learns what works for Character Biosciences specifically.
How is this page personalized for Character Biosciences?
This page was researched, audited, and generated using the same AI infrastructure we deploy for clients. The channel scores, team mapping, growth opportunities, and recommended agents are all based on real analysis of Character Biosciences's current marketing. This is a live demo of MH-1's capabilities.
Precision medicine visibility at scale for precision ophthalmology
The system gets smarter every cycle. Let's talk about building it for Character Biosciences.
Book a Strategy CallMonth-to-month. Cancel anytime.